BOAN BIOTECH (06955): Unusual trading volume changes and Darzalex (60MG) approved for launch in Bolivia.

BOAN BIOTECH (06955) announces that the board of directors has noted an increase in the trading volume of the company's shares (H shares) on January 9, 2026. After conducting a reasonable inquiry into the matter, the board confirms that, apart from the disclosures below, it is not aware of any reasons that may have led to the change in trading volume; any material that should be disclosed to avoid creating a false market for the company's securities; or any insider information that must be disclosed under Part XIV A of the Securities and Futures Ordinance of Hong Kong. The board has been notified by its controlling shareholder, LUYE PHARMA Group Limited (LUYE PHARMA, together with its subsidiaries referred to as the "LUYE PHARMA Group"), that on December 12, 2025, LUYE PHARMA's wholly-owned subsidiary Luye Geneora Holding Limited (the issuer) issued a number of convertible preference shares. These convertible preference shares give the holders the right to exchange the shares for the company's existing H shares held by LUYE PHARMA Group. As disclosed in the announcement, LUYE PHARMA and the issuer have agreed that following the issuance of the convertible preference shares, they will facilitate the transfer of 100.5 million H shares into the issuer's designated custodian account. This transfer is intended to ensure that the issuer can fulfill its obligation to deliver H shares when exercising the rights attached to the convertible preference shares. In compliance with the agreement, LUYE PHARMA Group arranged for its wholly-owned subsidiary, Shandong LUYE PHARMA Co., Ltd., to transfer 50 million H shares to the issuer on January 9, 2026. Furthermore, as disclosed, a total of 100.5 million H shares can be converted into the convertible preference shares. LUYE PHARMA Group has informed the board that, in accordance with the terms of the subscription agreement related to the convertible preference shares, further transfers of H shares to the issuer will be arranged. The board also confirms that there are currently no negotiations or agreements regarding proposed acquisitions or disposals that require disclosure under Rule 13.23 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, and the board is not aware of any matters that would be considered price-sensitive under Rule 13.09. The board is pleased to announce that its independently developed Denosumab Injection (60mg) (code: BA6101) has been approved for listing by the Bolivian National Drug and Health Technology Authority (AGEMED). BA6101 is a biosimilar to the reference drug Prolia, which is widely used globally for the treatment of osteoporosis. BA6101 has the same indications as the reference drug. Developed based on the company's global research and development strategy, BA6101 is planned for commercialization in multiple countries and regions worldwide. In 2022, BA6101 (Boween) became the first domestically-produced Denosumab Injection to be approved for listing in China. Currently, the application for market authorization for BA6101 in the UK is under review, and the company plans to submit applications for market authorization in Europe, the US, Japan, and other countries and regions. The research and development process for BA6101 strictly adheres to the biosimilar guidelines of China, the US, the EU, and Japan. Through a series of analyses, non-clinical studies, human pharmacokinetic studies, and clinical research, it has been confirmed that BA6101 is highly similar to the reference drug in terms of quality, safety, and efficacy, with no clinically significant differences. Additionally, the production of BA6101 follows the highest international standards, providing quality assurance for its overseas expansion. The company will collaborate with partners to promote the commercialization of BA6101 in Bolivia, improving access to Denosumab for patients and providing more treatment options. In addition to Bolivia, the company has reached strategic partnerships for the commercialization of BA6101 in other Latin American markets such as Brazil, the US, Southeast Asia, Hong Kong, and Macau. The company will accelerate its internationalization strategy by offering a range of high-quality domestic biopharmaceuticals, including BA6101, to meet the treatment needs of patients worldwide.